Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04469075
PHASE2

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Sponsor: Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.

Official title: The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2020-07-09

Completion Date

2026-07

Last Updated

2025-08-08

Healthy Volunteers

No

Interventions

DRUG

Clindamycin Phosphate

phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)

DRUG

Triamcinolone Acetonide

triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change

Locations (8)

Northwestern University

Evanston, Illinois, United States

Tufts Medical Center

Boston, Massachusetts, United States

Washington University School of Medicine

St Louis, Missouri, United States

Hackensack Meridian Health

Hackensack, New Jersey, United States

Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (All Protocol Activities)

Hauppauge, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Columbia University

New York, New York, United States

University of Cincinnati Medical Center

Cincinnati, Ohio, United States